Study suggests beta-blockers may elevate depression symptoms in post-MI patients

Research highlights the need to consider mental health impacts when prescribing beta-blockers to MI patients with preserved heart function.

Study: Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. Image Credit: Shidlovski/Shutterstock.comStudy: Short- and long-term effects of beta-blockers on symptoms of anxiety and depression in patients with myocardial infarction and preserved left ventricular function: a pre-specified quality of life sub-study from the REDUCE-AMI trial. Image Credit: Shidlovski/Shutterstock.com

In a recent study published in the European Heart Journal. Acute Cardiovascular Care, a group of researchers assessed the effects of beta-blockers on anxiety and depression symptoms in myocardial infarction (MI) (heart attack) patients with preserved left ventricular function.

Background

Beta-blockers have long been integral in preventing adverse outcomes following MI, initially proven effective in studies conducted before the widespread use of modern interventions like percutaneous coronary intervention and antithrombotic therapy.

They work by reducing myocardial oxygen demand and preventing cardiac remodeling and arrhythmias, yet they also have notable side effects, including bradycardia, hypotension, fatigue, exercise intolerance, and possible impacts on mental well-being, such as depression and anxiety.

Recent trials have yielded mixed findings on beta-blockers cardiovascular benefits in MI patients with preserved left ventricular function, highlighting a need for further research on their psychological effects.

About the study

The Randomized Evaluation of Decreased Usage of beta-bloCkErs (REDUCE-AMI) trial, conducted across 45 centers in Estonia, Sweden, and New Zealand, was a prospective, open-label, parallel-group, registry-based randomized clinical trial (RCT) assessing the effects of beta-blockers on MI patients with preserved left ventricular function.

This sub-study collected data on self-reported levels of anxiety and depression at three points: baseline, 6-10 weeks, and 12-14 months post-MI.

Eligible REDUCE-Quality of Life (RQoL) participants met criteria such as being aged ≥18, having confirmed obstructive coronary artery disease, preserved left ventricular ejection fraction (LVEF ≥50%), and providing informed consent.

Exclusion criteria included contraindications for beta-blockers or other non-study-related indications for their use. Additional eligibility for the RQoL sub-study included Swedish language proficiency.

Participants were assessed through self-reported questionnaires administered online or by mail, focusing on factors like psychological well-being, physical activity, and adherence.

Data analysis used linear mixed models adjusted for various baseline covariates, and multiple sensitivity analyses were conducted. The Hospital Anxiety and Depression Scale (HADS) measured primary outcomes.

Study results

Recruitment for the RQoL sub-study took place from August 2018 to June 2022, with follow-up concluding in June 2023. Out of 1,617 participants in the REDUCE-AMI main trial, 806 joined the RQoL sub-study.

These participants, predominantly male (77%) with a mean age of 64.7 years, were younger and more frequently smokers than non-participants in RQoL but showed no significant differences in baseline anxiety or depression scores.

Of the 806 RQoL participants, 682 (85%) completed follow-up 1 (6–10 weeks post-MI), and 657 (82%) completed follow-up 2 (12–14 months post-MI).

Participants who missed follow-ups tended to be younger, more often had diabetes, had lower education levels, smoked, used psychotropic medication, were non-Swedish-born, were less physically active, and reported higher anxiety and depression levels at baseline. Four participants died between the two follow-ups.

Adherence to the beta-blocker or non-beta-blocker allocation was tracked, revealing that 73 participants were non-adherent by follow-up 1, and 107 were non-adherent by follow-up 2, with some adherence data missing.

In the primary intention-to-treat analysis, the beta-blocker group displayed higher levels of depressive symptoms at both follow-ups, but there was no significant impact on anxiety scores.

Stratified analysis based on previous beta-blocker use showed different effects over time. Among participants not previously on beta-blockers, those randomized to beta-blocker treatment exhibited higher depression levels at follow-up 1, though this effect diminished by follow-up 2.

For participants already on beta-blockers at baseline, a significant increase in depressive symptoms was observed at follow-up 2.

Sensitivity analyses were conducted to assess the findings. Analyses using only complete cases yielded results consistent with the imputed analysis. Limiting the analysis to adherent participants showed similar results, with a slight reduction in the effect size for depressive symptoms at follow-up 1, which was no longer statistically significant.

When baseline values were excluded from adjustments, the difference between the beta-blocker and non-beta-blocker groups in depressive and anxiety symptoms was not significant.

Conclusions

To summarize, in the study, MI patients with preserved LVEF assigned to beta-blockers showed slightly higher depressive symptoms at 6–10 weeks and 12–14 months post-MI. However, effects remained below clinically significant thresholds.

No impact was observed on anxiety. Beta-blockers may induce depressive symptoms through neurotransmitter interactions and reduced engagement in enjoyable activities. Effects were more notable in patients already on beta-blockers, suggesting a potential cumulative impact.

Journal reference:
Vijay Kumar Malesu

Written by

Vijay Kumar Malesu

Vijay holds a Ph.D. in Biotechnology and possesses a deep passion for microbiology. His academic journey has allowed him to delve deeper into understanding the intricate world of microorganisms. Through his research and studies, he has gained expertise in various aspects of microbiology, which includes microbial genetics, microbial physiology, and microbial ecology. Vijay has six years of scientific research experience at renowned research institutes such as the Indian Council for Agricultural Research and KIIT University. He has worked on diverse projects in microbiology, biopolymers, and drug delivery. His contributions to these areas have provided him with a comprehensive understanding of the subject matter and the ability to tackle complex research challenges.    

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Kumar Malesu, Vijay. (2024, November 13). Study suggests beta-blockers may elevate depression symptoms in post-MI patients. News-Medical. Retrieved on November 14, 2024 from https://www.news-medical.net/news/20241113/Study-suggests-beta-blockers-may-elevate-depression-symptoms-in-post-MI-patients.aspx.

  • MLA

    Kumar Malesu, Vijay. "Study suggests beta-blockers may elevate depression symptoms in post-MI patients". News-Medical. 14 November 2024. <https://www.news-medical.net/news/20241113/Study-suggests-beta-blockers-may-elevate-depression-symptoms-in-post-MI-patients.aspx>.

  • Chicago

    Kumar Malesu, Vijay. "Study suggests beta-blockers may elevate depression symptoms in post-MI patients". News-Medical. https://www.news-medical.net/news/20241113/Study-suggests-beta-blockers-may-elevate-depression-symptoms-in-post-MI-patients.aspx. (accessed November 14, 2024).

  • Harvard

    Kumar Malesu, Vijay. 2024. Study suggests beta-blockers may elevate depression symptoms in post-MI patients. News-Medical, viewed 14 November 2024, https://www.news-medical.net/news/20241113/Study-suggests-beta-blockers-may-elevate-depression-symptoms-in-post-MI-patients.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Unraveling the psychological impact of COVID-19 on young minds